INCY Wutah pendapatan triwulanan Incyte Corporation

Simbol lan logo merek Incyte Pharma (INCY)

The quarterly sales growth rate for Incyte Corporation (INCY) demonstrates pressure due to the imminent expiration of patent protection for its primary product and R&D expenditures. The drug development environment is aggressive, and reliance on a single blockbuster creates vulnerability to industry behemoths. However, 14.20 reflects a fresh metric value, confirming that leadership in rare hemato-oncological therapies and the success of Jakafi ensure a stable cash generator.

Incyte Pharma (INCY) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Incyte (INCY) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
- data dhuwit lan arus kas:
Analisis umum perusahaan:Incyte Corp (INCY)
Barang unggulan incyte.com

The growth trajectory of Incyte Corporation (INCY) is clearly reflected through the percentage increase in quarterly sales. This indicator captures the rate of revenue change over the last three months relative to the previous period, revealing the immediate market reaction of demand to external factors. The calculation is based on a comparison of current receipts with the base quarter to assess the pace of business expansion. For the investor, an increase in this metric confirms the effectiveness of Jakafi's pricing power within the inelastic hematology segment.

Pesaing utama

HUTCHMED Corp - Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Nuvation Bio Inc.|DAWN: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Monopar Pharma MNPR|Wutah dodolan triwulanan INBX|Tingkat wutah pendapatan sajrone kuartal I-Mab Biopharma IMAB|Wutah dodolan triwulanan FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Tambahing pendapatan triwulanan|Nuvectis Pharma, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal CHRS (Coherus BioSciences)|Corbus Pharma - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRDF (cardiffoncology.com)|BYSI: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal BioAtla Corp (BCAB)|Wutah pendapatan kuartal marang kuartal Lixte Biotechnology Holdings, Inc.|CTXR: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CLRB|Wutah pendapatan triwulanan BioLineRx Corporation (BLRX)|Wutah pendapatan kuartal marang kuartal Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Dinamika pendapatan kuartal marang kuartal|KZIA: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Silexion Therapeutics|NuCana plc (NCNA) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan Chimerix, Inc|Wutah dodolan triwulanan CYCC|Wutah dodolan triwulanan G1 Therapeutics (GTHX)|Wutah pendapatan kuartal marang kuartal Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)